Tablet app tracks eye movements to spot chemo brain

NCT ID NCT05186948

Terminated Diagnosis Sponsor: Innodem Neurosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to develop and validate a tablet-based eye-tracking app to detect cancer-related cognitive impairment, often called 'chemo brain.' Researchers planned to enroll 230 participants, including breast cancer patients scheduled for chemotherapy and healthy volunteers. The app would track eye movements to measure attention and processing speed. However, the study was terminated early, so its effectiveness remains unproven.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Eye-tracking software application
What this could lead to: If successful, this could provide a simple, non-invasive way to detect and monitor brain fog in cancer patients using just a tablet.
What could go wrong: The study was terminated early, so results are limited. It is a small, early-stage development, and the technology may not prove accurate enough for clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE I-IIIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER-RELATED COGNITIVE IMPAIRMENT

Contacts and locations

Locations

McGill University Health Center-Cedar Cancer Center

Montreal, Quebec, H4A 3J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.